You just read:

Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AHA) Scientific Sessions 2011 Meeting

News provided by

Regado Biosciences, Inc.

Nov 14, 2011, 03:02 EST